Daya Drug Discoveries, Inc.
Dr. Raghavan Rajagopalan
University of Missouri, St. Louis
Benton Hall, R-109
One University Blvd.
St. Louis, MO 63121
Phone: 636-541-5863
Fax: 314-516-5342
Email: raghavanr@daya-dd.com
Daya Drug Discoveries
University of Missouri, St. Louis
Benton Hall, R-109
One University Blvd.
St. Louis, MO 63121
Phone: 636-541-5863
Fax: 314-516-5342
Email: raghavanr@daya-dd.com
The Sanskrit word "Daya" literally means compassion.
But Daya stands for more than just compassion; it is caring, empathy, sympathy, and kindlness.
Our Vision
DAYA’s vision is to introduce new, safe, and effective medications into the market for diagnosis and treatment of neurological disorders and cancer using a cutting-edge, rational design approach that is grounded on well-established and validated targets.
Our Mission
DAYA’s mission in the neuroscience program is to file an investigational new drug application (IND) with UD FDA for the newly discovered drug, DDD-028, for the treatment of chronic neuropathic pain. Current widely prescribed medications, gabapentin and pregabalin, are unsatisfactory.
DAYA’s mission in the abuse deterrence program is to optimize the new lead compound and identify a viable candidate for preclinical development for the treatment of methamphetamine addiction and the comorbid depression. Currently, there is no drug in the market for such an indication and DAYA hopes to satisfy this unmet need.
DAYA’s mission in the oncology program is to establish proof of concept of the new, powerful technology ‘LICHT,’ (light-induced chemotherapy) for the treatment of various cancers.
This is the Secondary Sidebar Widget Area. You can add content to this area by visiting your Widgets Panel and adding new widgets to this area.